FORSYTH DOUGLAS

SEC Form 4 insider
Inhibrx Biosciences, Inc. ($INBX)
1 thesis · first seen Sep 8, 2026
WindowThesesResolvedWinsWin rateAvg returnMedian return
1d
3d
1w
1m
3m
6m
1y

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$INBXSEC Form 4bullish
Long 2,500 shares of INBX
Bought 2,500 @ $114.65 avg · $286,617 · 2026-09-08

Form 4: FORSYTH DOUGLAS bought INBX

FORSYTH DOUGLAS (Director at Inhibrx Biosciences, Inc.) reported an open-market purchase of 2,500 shares of INBX at an average $114.65, roughly $286,617, in a Form 4 filed 2026-09-08.

View filing on SEC.gov →

End of results.